Upsher-Smith begins Phase III trial of intranasal midazolam for epilepsy seizure clusters
This article was originally published in Scrip
Executive Summary
Upsher-Smith Laboratories has started a Phase III trial evaluating the safety and efficacy of USL261, investigational intranasal midazolam, for the rescue treatment of seizures in patients on stable anti-epileptic drug (AED) regimens who require control of intermittent bouts of increased seizure activity, often referred to as seizure clusters.